127 research outputs found
Association between maternal glucose levels during pregnancy and gestational diabetes mellitus: an analytical cross-sectional study
Re: Previous caesarean delivery and the risk of unexplained stillbirth: retrospective cohort study and meta-analysis
Primary prevention of gestational diabetes for women who are overweight and obese: a randomised controlled trial
Does metformin reduce excess birthweight in offspring of obese pregnant women? A randomised controlled trial of efficacy, exploration of mechanisms and evaluation of other pregnancy complications
BackgroundMaternal obesity is associated with high birthweight, obesity and premature mortality in adult offspring, probably as a result of maternal hyperglycaemia and insulin resistance. We present the results of a trial designed to test the hypothesis that metformin will improve insulin sensitivity in obese pregnant women, thereby reducing the incidence of high-birthweight babies.ObjectiveTo determine the efficacy of metformin (up to 2500âmg daily) given to obese pregnant women in reducing the gestational age-, parity- and sex-adjusted birthweight centile of the baby.DesignDouble-blind, placebo-controlled, randomised controlled trial with embedded substudies.SettingFifteen NHS hospitals in the UK.ParticipantsPregnant women aged â„â16 years with a singleton fetus and a body mass index of â„â30âkg/m2.InterventionMetformin tablets (or placebo) administered between 12 and 16 weeksâ gestation until delivery of the baby.Main outcome measuresThe primary outcome measure was z-score corresponding to the gestational age-, parity- and sex-adjusted birthweight centile of live-born babies delivered at â„â24 weeksâ gestation. The main secondary outcome was maternal insulin resistance at 36 weeksâ gestation. Embedded substudies were included to assess the effect of metformin on insulin sensitivity using the hyperinsulinaemicâeuglycaemic clamp; endothelial function; maternal and fetal fat distribution using magnetic resonance imaging; placental expression of 11ÎČ-hydroxysteroid dehydrogenase types 1 and 2 and glucocorticoid receptor; and myometrial contractility and glycogen storage.ResultsWe randomised 449 women to either placebo (nâ=â223) or metformin (nâ=â226), of whom 434 were included in the final intention-to-treat analysis. Mean birthweight at delivery was 3463âg [standard deviation (SD) 660âg] in the placebo group and 3462âg (SD 548âg) in the metformin group. The estimated effect size of metformin on the primary outcome was non-significant [adjusted mean difference in z-score â0.029, 95% confidence interval (CI) â0.217 to 0.158; pâ=â0.7597]. There was no evidence of a reduction in the main secondary outcome of homeostatic model assessment â insulin resistance (HOMA-IR) at 36 weeksâ gestation (mean HOMA-IR 5.98 and 6.30 molar units in the placebo and metformin groups, respectively; adjusted mean ratio 0.974, 95% CI 0.865 to 1.097). Metformin had no effect on the combined adverse outcome of miscarriage, termination of pregnancy, stillbirth or neonatal death. Subjects taking metformin demonstrated increased insulin sensitivity [glucose disposal per unit plasma insulin difference between means during high-dose insulin 0.02âmg/kg, 95% CI 0.001 to 0.03âmg/kg (fat-free mass)/minute/”IU/l; pâ=â0.04] compared with those taking placebo and enhanced endogenous glucose production [difference between means 0.54âmg/kg, 95% CI 0.08 to 1.00âmg/kg (fat-free mass)/minute; pâ=â0.02]. There were no differences in endothelial function, maternal or fetal body fat distribution, placental expression of 11ÎČ-hydroxysteroid dehydrogenase types 1 and 2 and glucocorticoid receptor, or myometrial contractility and glycogen storage.ConclusionsMetformin has no clinically significant effect on birthweight centile in obese pregnant women. Follow-up studies of the children born to participants in the trial are required to determine whether or not there are any longer-term benefits or harms of maternal metformin for offspring weight, fat mass or metabolism.Trial registrationCurrent Controlled Trials ISRCTN51279843.FundingThis project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health Research partnership
Macrosomia and large for gestational age in Asia:One size does not fit all
Macrosomia, usually defined as infant birth weight of >= 4000 g, does not consider gestational age, sex, or country/region-specific differences in mean birth weight and maternal body weight. This issue is particularly relevant for Asia, where 60% of the world's population lives, due to variations in maternal size and birth weights across populations. Large for gestational age (LGA), defined as birth weight > 90th centile, is a more sensitive measure as it considers gestational age and sex, though it is dependent on the choice of growth charts. We aimed to review reporting of macrosomia and LGA in Asia. We reviewed the literature on prevalence and risk of macrosomia and LGA in Asia over the last 29 years. Prevalence of macrosomia ranged from 0.5% (India) to 13.9% (China) while prevalence of LGA ranged from 4.3% (Korea) to 22.1% (China), indicating substantial variation in prevalence within and between Asian countries. High pre-pregnancy body mass index, excessive gestational weight gain, and impaired glucose tolerance conferred risk of macrosomia/LGA. Incidence of macrosomia and LGA varies substantially within and between Asian countries, as do the growth charts and definitions. The latter makes it impossible to make comparisons but suggests differences in intrauterine growth between populations. Reporting LGA, using standardized country/regional growth charts, would better capture the incidence of high birth weight and allow for comparison and identification of contributing factors. Better understanding of local drivers of excessive intrauterine growth could enable development of improved strategies for prevention and management of LGA
Survey on testing for gestational diabetes mellitus in Australia
We surveyed members of National Association of Diabetes Centres (NADC) assessing use of new Australasian Diabetes In Pregnancy Society (ADIPS) and Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG) Gestational Diabetes Mellitus (GDM) diagnostic guidelines in Australia. We found piecemeal adoption of recommended changes, with cessation of the 50 g glucose challenge test (GCT) universal, early screening implementation common, but by varied methodologies, and new diagnostic criteria acceptance far from complete with significant workload increases almost universal
Characteristics of insulin secretion patterns in Japanese women with overt diabetes and gestational diabetes defined according to the International Association of Diabetes and Pregnancy Study Groups criteria
- âŠ